Keira Bell
Detransitioner, campaigner and legal pioneer
Keira Bell's High Court case against the Tavistock clinic reshaped the conversation about medical treatment of gender-questioning youth across Europe. Her account — from puberty blockers and testosterone to detransition — confronts the clinical protocols that spread from the Netherlands outward across the continent, and raises questions that Sweden, Finland, France and Germany are still working through.
Keira Bell was referred to the Tavistock Centre's Gender Identity Development Service as a troubled teenager, and was prescribed puberty blockers, then testosterone, before undergoing a double mastectomy. She later detransitioned and brought a landmark High Court case — Bell v Tavistock (2020) — arguing that children cannot give informed consent to puberty blockers. Although the Court of Appeal overturned the ruling in 2021, her case set off a reckoning in British medicine that led to the 2024 Cass Review and sent shockwaves far beyond the UK.
For continental Europe, those shockwaves arrived on already-shifting ground. The clinical model used on Bell did not originate in Britain but in the Netherlands — the Dutch Protocol developed at Amsterdam's VU University Medical Center became the global blueprint for gender clinics. Sweden's Karolinska Hospital and Finland's health authorities had already begun restricting puberty blockers for minors before the Cass Review published; France, Denmark and Norway have since issued comparable cautions. Her case accelerated a continent-wide question: did these interventions ever rest on the evidence base that clinicians claimed?
In The DARK Reality Behind 'Gender Affirming Care' — Keira Bell (#2) (Beyond Gender, February 2025), Bell speaks with Stella O'Malley and Dr Bret Alderman about what it actually cost to challenge a medical institution — personally and legally. She describes the informed-consent failures she experienced as structural rather than incidental, and reflects on the silence of professionals who, she suggests, knew more than they said.
For European clinicians and policymakers, her account is uncomfortably precise. The protocols, age thresholds and institutional pressures she describes did not stop at the English Channel. This episode works less as a British story than as a clinical audit of a shared era in gender medicine.
